- Home
- PFLT vs RGNX Comparison
PFLT vs RGNX Comparison
Compare PFLT & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFLT | RGNX |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.9M | 761.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | PFLT | RGNX |
|---|---|---|
| Price | $9.46 | $15.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $10.75 | ★ $30.78 |
| AVG Volume (30 Days) | ★ 1.1M | 691.4K |
| Earning Date | 02-09-2026 | 03-12-2026 |
| Dividend Yield | ★ 13.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $261,427,000.00 | $161,318,000.00 |
| Revenue This Year | $11.75 | $133.58 |
| Revenue Next Year | N/A | $45.08 |
| P/E Ratio | $13.15 | ★ N/A |
| Revenue Growth | 40.28 | ★ 91.30 |
| 52 Week Low | $8.40 | $5.04 |
| 52 Week High | $11.50 | $15.84 |
Technical Indicators
Market Signals| Indicator | PFLT | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 58.09 |
| Support Level | $9.30 | $13.40 |
| Resistance Level | $9.75 | $15.19 |
| Average True Range (ATR) | 0.16 | 0.93 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 42.27 | 75.76 |
Price Performance
Historical ComparisonAbout PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.